These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25411)

  • 1. Hypophosphatemic vitamin D-resistant rickets: metabolic balance studies in a child receiving 1,25 dihydroxyvitamin D3, phosphate, and ascorbic acid.
    Hirschman GH; DeLuca HF; Chan JC
    Pediatrics; 1978 Mar; 61(3):451-7. PubMed ID: 25411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
    Drezner MK; Lyles KW; Haussler MR; Harrelson JM
    J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of 1,25-dihydroxycholecalciferol on renal tubular reabsorption of phosphate, intestinal absorption of calcium and bone histology in hypophosphataemic renal tubular rickets.
    Russell RG; Smith R; Preston C; Walton RJ; Woods CG; Henderson RG; Norman AW
    Clin Sci Mol Med; 1975 Mar; 48(3):177-86. PubMed ID: 163719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone response to phosphate and vitamin D metabolites in the hypophosphatemic male mouse.
    Marie PJ; Travers R; Glorieux FH
    Calcif Tissue Int; 1982 Mar; 34(2):158-64. PubMed ID: 6282410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hypophosphataemic vitamin D-resistant rickets with massive doses of 1 alpha-hydroxy-vitamin D3 during childhood.
    Seino Y; Shimotsuji T; Ishii T; Ishida M; Ikehara C; Yamaoka K; Yabuuchi H; Dokoh S
    Arch Dis Child; 1980 Jan; 55(1):49-53. PubMed ID: 6246841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets.
    Glorieux FH; Marie PJ; Pettifor JM; Delvin EE
    N Engl J Med; 1980 Oct; 303(18):1023-31. PubMed ID: 6252463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypophosphatemic rickets: effect of 1 alpha, 25-dihydroxyvitamin D3 on growth and mineral metabolism.
    Chan JC; Bartter FC
    Pediatrics; 1979 Oct; 64(4):488-95. PubMed ID: 492815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of genetically hypophosphatemic mice by 1 alpha-hydroxyvitamin D3 but not 1,25-dihydroxyvitamin D3.
    Beamer WG; Wilson MC; DeLuca HF
    Endocrinology; 1980 Jun; 106(6):1949-55. PubMed ID: 6892799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal hypophosphatemic rickets: growth acceleration after long-term treatment with 1,25-dihydroxyvitamin-D3.
    Chan JC; Lovinger RD; Mamunes P
    Pediatrics; 1980 Sep; 66(3):445-54. PubMed ID: 6893489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supranormal 25-hydroxyvitamin D and subnormal 1,25-dihydroxyvitamin D: their role in X-linked hypophosphatemic rickets.
    Chesney RW; Mazess RB; Rose P; Hamstra AJ; DeLuca HF
    Am J Dis Child; 1980 Feb; 134(2):140-3. PubMed ID: 6243443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum 1,25-dihydroxyvitamin D concentration in hypophosphatemic vitamin D-resistant rickets.
    Delvin EE; Glorieux FH
    Calcif Tissue Int; 1981; 33(2):173-5. PubMed ID: 6260313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actions of 1,25-dihydroxycholecalciferol in patients with hypophosphatemic, vitamin-D-resistant rickets.
    Brickman AS; Coburn JW; Kurokawa K; Bethune JE; Harrison HE; Norman AW
    N Engl J Med; 1973 Sep; 289(10):495-8. PubMed ID: 4353218
    [No Abstract]   [Full Text] [Related]  

  • 13. Autosomal hypophosphataemic bone disease responds to 1,25-(OH)2D3.
    Scriver CR; Reade T; Halal F; Costa T; Cole DE
    Arch Dis Child; 1981 Mar; 56(3):203-7. PubMed ID: 7212758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of long-term treatment with massive doses of 1 alpha-hydroxyvitamin D3 on calcium-phosphate balance in patients with vitamin D-dependent rickets type II.
    Takeda E; Yokota I; Saijo T; Kawakami I; Ito M; Kuroda Y
    Acta Paediatr Jpn; 1990 Feb; 32(1):39-43. PubMed ID: 2158205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term therapy of viramin D-resistant richets with 25-hydroxycholecalciferol.
    Puschett JB; Genel M; Rastegar A; Anast C; DeLuca HF; Friedman A
    Clin Pharmacol Ther; 1975 Feb; 17(2):202-11. PubMed ID: 164313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The kidney as an endocrine organ involved in the function of vitamin D.
    DeLuca HF
    Am J Med; 1975 Jan; 58(1):39-47. PubMed ID: 163578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute biochemical effects of growth hormone treatment compared with conventional treatment in familial hypophosphataemic rickets.
    Patel L; Clayton PE; Brain C; Pelekouda E; Addison GM; Price DA; Mughal MZ
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):687-96. PubMed ID: 8759181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of hypophosphataemic vitamin D-resistant rickets treated with initial massive doses of 1 alpha-hydroxy-vitamin D3 alone.
    Muraki K; Nishi Y; Tsuda K; Yoshimitsu K; Usui T
    Acta Paediatr Scand; 1983 Sep; 72(5):763-8. PubMed ID: 6314737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ionic control of 1,25-dihydroxyvitamin D3 production in isolated chick renal tubules.
    Bikle DD; Rasmussen H
    J Clin Invest; 1975 Feb; 55(2):292-8. PubMed ID: 236326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII).
    al-Aqeel A; Ozand P; Sobki S; Sewairi W; Marx S
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):229-37. PubMed ID: 8396512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.